Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now. On November 12, Apellis Pharmaceuticals announced that a post hoc analysis of the Phase 3 GALE extension study ...

Thus far in 2025, notable developments in retinal disease have included several newsworthy associations with the widely used GLP-1 agonist drugs for diabetes and weight loss, a study of patient ...

– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a ...

A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown genetic cause of hereditary optic atrophy, a degenerative disease of the ...

A nationwide cohort study of more than 4 million adults showed that people with allergic diseases were nearly one third more likely to develop optic neuritis than those without such conditions, with ...

A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Mary is the bedrock of her family. “She’s the one we all go to,” says her son Eric. “She’s selfless, extremely sweet, very personable—but she can also be very feisty.” So when she returned from an eye ...

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in presymptomatic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...